Αρχική World News Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC World News Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC Από Ogkologos - 20 Αυγούστου, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients... 9 Ιουλίου, 2026 Cancer in My Community: Providing Supportive Care in Serbia 14 Οκτωβρίου, 2021 New plan unveiled to tackle Scotland’s cancer crisis 16 Ιουνίου, 2023 Ivosidenib with Chemotherapy New Option for Some People with AML 13 Μαΐου, 2022 Φόρτωση περισσοτέρων HOT NEWS Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia ESMO Launches Living Guidelines to Enhance the Usability of its Clinical...